Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.34
OFIX's Cash to Debt is ranked higher than
66% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. OFIX: 1.34 )
OFIX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 1.34

Equity to Asset 0.76
OFIX's Equity to Asset is ranked higher than
80% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. OFIX: 0.76 )
OFIX' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.85
Current: 0.76

0.36
0.85
F-Score: 4
Z-Score: 4.85
M-Score: -3.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -2.69
OFIX's Operating margin (%) is ranked higher than
64% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. OFIX: -2.69 )
OFIX' s 10-Year Operating margin (%) Range
Min: -49.44   Max: 29.29
Current: -2.69

-49.44
29.29
Net-margin (%) -7.73
OFIX's Net-margin (%) is ranked higher than
61% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. OFIX: -7.73 )
OFIX' s 10-Year Net-margin (%) Range
Min: -43.98   Max: 34.01
Current: -7.73

-43.98
34.01
ROE (%) -9.09
OFIX's ROE (%) is ranked higher than
60% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. OFIX: -9.09 )
OFIX' s 10-Year ROE (%) Range
Min: -71.87   Max: 40.27
Current: -9.09

-71.87
40.27
ROA (%) -6.89
OFIX's ROA (%) is ranked higher than
61% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. OFIX: -6.89 )
OFIX' s 10-Year ROA (%) Range
Min: -31.59   Max: 27.4
Current: -6.89

-31.59
27.4
ROC (Joel Greenblatt) (%) -4.19
OFIX's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. OFIX: -4.19 )
OFIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -113.98   Max: 66.23
Current: -4.19

-113.98
66.23
Revenue Growth (%) -12.10
OFIX's Revenue Growth (%) is ranked higher than
54% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. OFIX: -12.10 )
OFIX' s 10-Year Revenue Growth (%) Range
Min: -12.1   Max: 22.2
Current: -12.1

-12.1
22.2
EBITDA Growth (%) -46.80
OFIX's EBITDA Growth (%) is ranked higher than
53% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. OFIX: -46.80 )
OFIX' s 10-Year EBITDA Growth (%) Range
Min: -46.8   Max: 63.2
Current: -46.8

-46.8
63.2
» OFIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

OFIX Guru Trades in Q4 2013

Jim Simons 179,179 sh (+94.38%)
Mario Gabelli 98,325 sh (+5.02%)
Richard Snow 94,045 sh (-9.41%)
Arnold Schneider 112,857 sh (-20%)
Diamond Hill Capital 372,646 sh (-50.4%)
» More
Q1 2014

OFIX Guru Trades in Q1 2014

Paul Tudor Jones 8,329 sh (New)
Chuck Royce 60,000 sh (New)
Joel Greenblatt 26,468 sh (New)
Arnold Schneider 119,993 sh (+6.32%)
Diamond Hill Capital 391,926 sh (+5.17%)
Mario Gabelli 99,725 sh (+1.42%)
Richard Snow Sold Out
Jim Simons 36,379 sh (-79.7%)
» More
Q2 2014

OFIX Guru Trades in Q2 2014

Jim Simons 113,769 sh (+212.73%)
Diamond Hill Capital 454,236 sh (+15.9%)
Paul Tudor Jones 9,324 sh (+11.95%)
Joel Greenblatt Sold Out
Chuck Royce 59,300 sh (-1.17%)
Mario Gabelli 98,125 sh (-1.6%)
Arnold Schneider 111,938 sh (-6.71%)
» More
Q3 2014

OFIX Guru Trades in Q3 2014

Paul Tudor Jones 18,323 sh (+96.51%)
Diamond Hill Capital 527,131 sh (+16.05%)
Chuck Royce 59,300 sh (unchged)
Mario Gabelli 97,625 sh (-0.51%)
Arnold Schneider 108,113 sh (-3.42%)
Jim Simons 50,783 sh (-55.36%)
» More
» Details

Insider Trades

Latest Guru Trades with OFIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Sold Out 0.01%$29.68 - $35.8 $ 28.18-13%0
Richard Snow 2014-03-31 Sold Out 0.09%$20.5 - $30.38 $ 28.1823%0
Joel Greenblatt 2014-03-31 New Buy0.01%$20.5 - $30.38 $ 28.1823%26468
Arnold Schneider 2013-09-30 Add 588.67%0.23%$21.55 - $28.58 $ 28.1816%141068
David Dreman 2013-09-30 Sold Out 0.17%$21.55 - $28.58 $ 28.1816%0
Joel Greenblatt 2013-09-30 Sold Out 0.14%$21.55 - $28.58 $ 28.1816%0
Richard Snow 2013-09-30 Add 130.52%0.05%$21.55 - $28.58 $ 28.1816%103815
Joel Greenblatt 2013-06-30 New Buy0.14%$26.19 - $35.76 $ 28.18-6%125677
Richard Snow 2013-06-30 New Buy0.06%$26.19 - $35.76 $ 28.18-6%45035
David Dreman 2013-03-31 New Buy0.29%$35.87 - $39.94 $ 28.18-25%305324
Arnold Schneider 2013-03-31 Reduce -34.03%0.04%$35.87 - $39.94 $ 28.18-25%19484
Joel Greenblatt 2012-12-31 Sold Out 0.16%$36.47 - $45.52 $ 28.18-28%0
Joel Greenblatt 2012-09-30 New Buy0.16%$40.25 - $44.9 $ 28.18-33%53003
Arnold Schneider 2012-09-30 Reduce -40.4%0.1%$40.25 - $44.9 $ 28.18-33%36885
Joel Greenblatt 2012-03-31 Sold Out 0.09%$34.28 - $42.92 $ 28.18-24%0
Joel Greenblatt 2011-12-31 Add 174.1%0.06%$30.84 - $36.03 $ 28.18-16%21048
Arnold Schneider 2011-12-31 Reduce -20.58%0.06%$30.84 - $36.03 $ 28.18-16%88283
Joel Greenblatt 2011-09-30 Reduce -37.89%0.03%$33.61 - $44.52 $ 28.18-27%7679
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.60
OFIX's P/B is ranked higher than
87% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. OFIX: 1.60 )
OFIX' s 10-Year P/B Range
Min: 0.77   Max: 3.17
Current: 1.6

0.77
3.17
P/S 1.30
OFIX's P/S is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. OFIX: 1.30 )
OFIX' s 10-Year P/S Range
Min: 0.31   Max: 3.87
Current: 1.3

0.31
3.87
PFCF 37.10
OFIX's PFCF is ranked higher than
86% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. OFIX: 37.10 )
OFIX' s 10-Year PFCF Range
Min: 6.45   Max: 535.73
Current: 37.1

6.45
535.73
EV-to-EBIT -47.96
OFIX's EV-to-EBIT is ranked lower than
54% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. OFIX: -47.96 )
OFIX' s 10-Year EV-to-EBIT Range
Min: -61.4   Max: 128.1
Current: -47.96

-61.4
128.1
Current Ratio 5.02
OFIX's Current Ratio is ranked higher than
85% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. OFIX: 5.02 )
OFIX' s 10-Year Current Ratio Range
Min: 1.56   Max: 5.15
Current: 5.02

1.56
5.15
Quick Ratio 3.35
OFIX's Quick Ratio is ranked higher than
80% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. OFIX: 3.35 )
OFIX' s 10-Year Quick Ratio Range
Min: 1.13   Max: 4.2
Current: 3.35

1.13
4.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 17.40
OFIX's Price/Net Current Asset Value is ranked higher than
80% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. OFIX: 17.40 )
OFIX' s 10-Year Price/Net Current Asset Value Range
Min: 6.14   Max: 715.65
Current: 17.4

6.14
715.65
Price/Tangible Book 2.00
OFIX's Price/Tangible Book is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. OFIX: 2.00 )
OFIX' s 10-Year Price/Tangible Book Range
Min: 1.48   Max: 104.21
Current: 2

1.48
104.21
Price/DCF (Projected) 1.20
OFIX's Price/DCF (Projected) is ranked higher than
94% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. OFIX: 1.20 )
OFIX' s 10-Year Price/DCF (Projected) Range
Min: 0.55   Max: 3.26
Current: 1.2

0.55
3.26
Price/Median PS Value 0.90
OFIX's Price/Median PS Value is ranked higher than
83% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. OFIX: 0.90 )
OFIX' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.3
Current: 0.9

0.36
3.3
Earnings Yield (Greenblatt) -2.10
OFIX's Earnings Yield (Greenblatt) is ranked higher than
64% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. OFIX: -2.10 )
OFIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.1   Max: 14.1
Current: -2.1

-2.1
14.1
Forward Rate of Return (Yacktman) 3.61
OFIX's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. OFIX: 3.61 )
OFIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 27.6
Current: 3.61

2.9
27.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:OFX.Germany
Orthofix International NV was formed on October 19, 1987 under the laws of the Netherlands Antilles. The Company is a diversified, medical device company engaged in developing and delivering repair and regenerative solutions to the spine and orthopedic markets. Its products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. The Company designs, develops, manufactures, markets and distributes medical devices used mainly by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products human cellular and tissue based products ('HCT/P products') used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, and external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. The Company has administrative and training facilities in the United States, Brazil, the United Kingdom, France, Germany, Puerto Rico and Italy and manufacturing facilities in the U.S. and Italy. The Company directly distributes its products in the U.S., the United Kingdom, Italy, Germany, France, Belgium, Brazil, Australia, and Puerto Rico. The Company manages its business by its four strategic business units (SBUs), which are comprised of BioStim, Biologics, Extremity Fixation, Spine Fixation. The BioStim SBU manufactures, distributes, and provides support services for a portfolio of devices for enhancing bone fusion that utilize the Company's patented pulsed electromagnetic (PEMF) technology. These Food and Drug Administration-approved Class 3 medical devices are indicated as an adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion as well as a therapeutic treatment for non-healing fractures outside of the spine. The Biologics SBU provides a portfolio of regenerative products that allow physicians to successfully treat various spinal and orthopedic conditions. This SBU specializes in the marketing of the Company's regeneration tissue forms. Biologics distributes its tissues through a network of distributors, sales, representatives and affiliates to market to hospitals, doctors, and other healthcare providers, mainly in the U.S. The Company's partnership with MTF allows it to exclusively market its Trinity Evolution and Trinity Elitetissue forms for musculoskeletal defects to enhance bone fusion. The Extremity Fixation SBU offers products that allow physicians to successfully treat various orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company's orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. The Spine
» More Articles for OFIX

Headlines

Articles On GuruFocus.com
Three Growing Companies Worth a Second Look Oct 09 2013 
Weekly CEO Buys Highlight: MOSY, PMT, APA, CUBI, OFIX May 26 2013 
Weekly 3-Year Low Highlights: SBY, PER, OFIX, EDG May 14 2013 
Orthofix International N.V. Reports Operating Results (10-K) Mar 03 2011 
Orthofix International N.V. (OFIX) CEO Alan Milinazzo buys 1,100 Shares Nov 09 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Oct 28 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Jul 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Apr 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Nov 06 2009 
Orthofix International Announces Record Revenue in 2nd Quarter 2009 Jul 30 2009 

More From Other Websites
Orthofix International Provides Update Regarding NASDAQ Listing Matters Nov 24 2014
5:40 pm Orthofix announces it continues to work to complete the procedures needed to file its two... Nov 24 2014
Orthofix International Provides Update Regarding NASDAQ Listing Matters Nov 24 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 24 2014
Orthofix Initiates First US Clinical Study of Osteogenesis Stimulation for Odontoid Fractures Nov 10 2014
Orthofix Initiates First US Clinical Study of Osteogenesis Stimulation for Odontoid Fractures Nov 10 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers Nov 03 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Other Events Oct 10 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Oct 06 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers, Other... Sep 25 2014
Orthofix Provides Finance and Restatement Update Sep 24 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Sep 23 2014
Orthofix Announces Appointment of Luke T. Faulstick to Board of Directors Sep 22 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers, Other... Sep 08 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Entry into a Material Definitive Agreement, Notice of... Aug 19 2014
Orthofix Updates Filing Status Aug 19 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2014
Orthofix Announces Delay of Form 10-Q Filing and Provides Preliminary Second Quarter 2014 Net Sales... Aug 06 2014
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 19 2014
U.S. Companies Catch World Cup Fever with Foreign Mergers Jun 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK